NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 8, 2014, Pages 1704-1715

  Barman, Scott A ^b   Chen, Feng ^a,b   Su, Yunchao ^b   Dimitropoulou, Christiana ^b   Wang, Yusi ^b   Catravas, John D ^b   Han, Weihong ^b   Orfi, Laszlo ^c,g   Szantai Kis, Csaba ^c   Keri, Gyorgy ^c,g   Szabadkai, Istvan ^c   Barabutis, Nektarios ^b   Rafikova, Olga ^b   Rafikov, Ruslan ^b   Black, Stephen M ^b   Jonigk, Danny ^e   Giannis, Athanassios ^d   Asmis, Reto ^f   Stepp, David W ^b   Ramesh, Ganesan ^b   Fulton, David J R ^b   more..

^a NANJING MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Vichem Chemie Ltd   (Hungary)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Adventitia; Fibroblast; NADPH oxidase; Pulmonary artery

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CATALASE; CD11B ANTIGEN; DIPHENYLIODONIUM SALT; FIBRONECTIN; GKT 136901; HEAT SHOCK PROTEIN 90; MESSENGER RNA; MONOCROTALINE; OXIDOREDUCTASE INHIBITOR; PROTEIN P22; PROTEIN P47; PROTEIN P67; PROTEOCHONDROITIN SULFATE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMOOTH MUSCLE ACTIN; TENASCIN; TENASCIN N; THROMBOSPONDIN; THROMBOSPONDIN 4; THY 1 ANTIGEN; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VCC 202273; VCC 588646; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL WALL; CARDIOPULMONARY FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DENSITOMETRY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HEART OUTPUT; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HYPERTENSIVE VASCULAR REMODELING; IMMUNOFLUORESCENCE; LUNG CIRCULATION; LUNG FIBROBLAST; MONOCYTE; NONHUMAN; PATHOGENESIS; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ADVENTITIA; FIBROBLAST; NADPH OXIDASE; PULMONARY ARTERY;

ADVENTITIA; ANIMALS; ANOXIA; ANTIHYPERTENSIVE AGENTS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; FIBROBLASTS; HEK293 CELLS; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INDOLES; MALE; MICE; MICE, INBRED C57BL; MONOCROTALINE; NADPH OXIDASE; PULMONARY ARTERY; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84904564698     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303848     Document Type: Article

References (55)

1. Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB. Pathology of pulmonary hypertension. Clin Chest.Med. 2013;34:639-650.
2. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99:675-691.
3. Crosswhite P, Sun Z. Molecular mechanisms of pulmonary arterial remodeling. Mol Med. 2014;20:191-201.
4. Cogolludo A, Moreno L, Villamor E. Mechanisms controlling vascular tone in pulmonary arterial hypertension: implications for vasodilator therapy. Pharmacology. 2007;79:65-75.
5. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982- 2006. Eur Respir J. 2007;30:1103-1110.
6. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med. 2004;169:764-769.
7. Liu JQ, Zelko IN, Erbynn EM, Sham JS, Folz RJ. Hypoxic pulmonary hypertension: role of superoxide and NADPH oxidase (gp91phox). Am J Physiol Lung Cell Mol Physiol. 2006;290:L2-10.
8. Dennis KE, Aschner JL, Milatovic D, Schmidt JW, Aschner M, Kaplowitz M R, Zhang Y, Fike CD. NADPH oxidases and reactive oxygen species at different stages of chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol. 2009;297:L596-L607.
9. Masri FA, Comhair SA, Dostanic-Larson I, Kaneko FT, Dweik RA, Arroliga AC, Erzurum SC. Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension. Clin Transl Sci. 2008;1:99-106.
10. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg-Maitland M, Thébaud B, Husain AN, Cipriani N, Rehman J. Epigenetic attenuation of mitochondrial superoxide dis mutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation. 2010;121:2661-2671.
11. Lassègue B, Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol. 2010;30:653-661.
12. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol. 2000;2 79:L1005-L1028.
13. Nisimoto Y, Jackson HM, Ogawa H, Kawahara T, Lambeth JD. Constitutive NADPH-dependent electron transferase activity of the Nox4 dehydrogenase domain. Biochemistry. 2010;49:2433-2442.
14. Chen F, Haigh S, Barman S, Fulton DJ. From form to function: the role of Nox4 in the cardiovascular system. Front Physiol. 2012;3:412.
15. Dikalova A, Clempus R, Lassègue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, Taylor WR, Schmidt HH, Owens GK, Lambeth JD, Griendling KK. Nox1 overexpression potentiates angiotensin II-induced hyperten sion and vascular smooth muscle hypertrophy in transgenic mice. Circulation. 2005;112:2668-2676.
16. Basset O, Deffert C, Foti M, Bedard K, Jaquet V, Ogier-Denis E, Krause KH. NADPH oxidase 1 def iciency alters caveolin phosphorylation and angiotensin II-receptor localization in vascular smooth muscle. Antioxid Redox Signal. 2009;11:2371-2384.
17. Li S, Tabar SS, Malec V, Eul BG, Klepetko W, Weis smann N, Grimminger F, Seeger W, Rose F, Hänze J. NOX4 regulates ROS levels under normoxic and hypoxic conditions, triggers proliferation, and inhibits apoptosis in pulmonary artery adventitial fibroblasts. Antioxid Redox Signal. 2008;10:1687-1698.
18. Nisbet RE, Graves AS, Kleinhenz DJ, Rupnow HL, Reed AL, Fan TH, Mitchell PO, Sutliff RL, Hart CM. The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice. Am J Respir Cell Mol Biol. 2009;40:601-609.
19. Mittal M, Roth M, König P, et al. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res. 2007;101:258-267.
20. Green DE, Murphy TC, Kang BY, Kleinhenz JM, Szyndralewiez C, Page P, Sutliff RL, Hart CM. The Nox4 inhibitor GKT137831 attenuates hypoxia-ind uced pulmonary vascular cell proliferation. Am J Respir Cell Mol Biol. 2012;47:718-726.
21. Coflesky JT, Jones RC, Reid LM, Evans JN. Mechanical properties and structure of isolated pulmonary arteries remodeled by chronic hyperoxia. Am Rev Respir Dis. 1987;136:388-394.
22. Sanz J, Kariisa M, Dellegrottaglie S, Prat-González S, Garcia MJ, Fuster V, Rajagopalan S. Evaluation of pulmonary art ery stiffness in pulmonary hypertension with cardiac magnetic resonance. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:286-295.
23. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994;1:71-81.
24. Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol. 2011;11:427-435.
25. Rey FE, Pagano PJ. The reactive adventitia: fibroblast oxidase in vascular function. Arterioscler Thromb Vasc Biol. 2002;22:1962-1971.
26. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, Pennathur S, Martinez FJ, Thannickal VJ. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009;15:1077-1081.
27. Chen F, Pandey D, Chadli A, Catravas JD, Chen T, Fulton DJ. Hsp90 regulates NADPH oxidase activity and is necessary for superoxide but not hydrogen peroxide production. Antioxid Redox Signal. 2011;14:2107-2119.
28. Rhoades RA, Packer CS, Roepke DA, Jin N, Meiss RA. Reactive oxygen species alter contractile properties of pulmonary arterial smooth muscle. Can J Physiol Pharmacol. 1990;68:1581-1589.
29. Fresquet F, Pourageaud F, Leblais V, Brandes RP, Savineau JP, Marthan R, Muller B. Role of reactive oxygen species and gp91phox in endothelial dysfunction of pulmonary arte ries induced by chronic hypoxia. Br J Pharmacol. 2006;148:714-723.
30. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1013-L1032.
31. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, Taraseviciene-Stewart L, Sung Y, Kraskauskas D, Farkas D, Conrad DH, Nicolls MR, Voelkel NF. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol. 2012;302:L977-L991.
32. Sturrock A, Cahill B, Norman K, Huecksteadt TP, Hill K, Sanders K, Karwande SV , Stringham JC, Bull DA, Gleich M, Kennedy TP, Hoidal JR. Transforming growth factor-beta1 induces Nox4 NAD(P)H oxidase and reactive oxygen species-dependent proliferation in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2006;290:L661-L673.
33. Ismail S, Sturrock A, Wu P, Cahill B, Norman K, Huecksteadt T, Sanders K, Kennedy T, Hoidal J. NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol. 2009;296:L489-L499.
34. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 2009;54:668?675.
35. Veit F, Pak O, Egemnazarov B, Roth M, Kosanovic D, Seimetz M, Sommer N, Ghofrani HA, Seeger W, Grimminger F, Brandes RP, Schermuly RT, Weissmann N. Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. Antioxid Redox Signal. 2013;19:2213-2231.
36. Borbély G, Szabadkai I, Horváth Z, Markó P, Varga Z, Breza N, Baska F, Vántus T, Huszár M, Geiszt M, Hunyady L, Buday L, Orfi L, Kéri G. Small-molecule inhibitors of NADPH oxidase 4. J Med Chem. 2010;53:6758-6762.
37. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou- Molango S, Gradia A, Duboux G, Merlot C, Heitz F, Szyndralewiez C, Page P. First in class, potent, and orally bioavailable NA DPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem. 2010;53:7715-7730.
38. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sores cu D. NAD(P)H oxidase 4 mediates transforming growth factor- beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res. 2005;97:900-907.
39. Amara N, Goven D, Prost F, Muloway R, Crestani B, Boczkowski J. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts. Thorax. 2010;65:733-738.
40. Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, Ausoni S, Pauletto P. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res. 2001;89:1111-1121.
41. Majesky MW, Dong XR, Hoglund V, Mahoney WM Jr, Daum G. The adventitia: a dynamic interface containing resident progenitor cells. Arterioscler Thromb Vasc Biol. 2011;31:1530-1539.
42. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
43. Maiellaro K, Taylor WR. The role of the adventitia in vascular inflammation. Cardiovasc Res. 2007;75:640-648.
44. Enzerink A, Vaheri A. Fibroblast activation in vascular inflammation. J Thromb Haemost. 2011;9:619-626.
45. Chan EC, Peshavariya HM, Liu GS, Jiang F, Lim SY, Dusting GJ. Nox4 modulates collagen production stimulated by transforming growth factor β1 in vivo and in vitro. Biochem Biophys Res Commun. 2013;430:918-925.
46. Bellini A, Mattoli S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest. 2007;87:858-870.
47. Ma W, Han W, Greer PA, T uder RM, Toque HA, Wang KK, Caldwell RW, Su Y. Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest. 2011;121:4548-4566.
48. Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW. Altered bone morphogenetic protein and transforming growth factor- beta signaling in rat models of pulmonary hypertensio n: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009;119:566-576.
49. Thannickal VJ, Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J Biol Chem. 1995;270:30334-30338.
50. Clempus RE, Sorescu D, Dikalova AE, Pounkova L, Jo P, Sorescu GP, Schmidt HH, Lassègue B, Griendling KK. Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol. 2007;27:42-48.
51. Derrett-Smith EC, Dooley A, Gilbane AJ, Trinder SL, Khan K, Baliga R, Holmes AM, Hobbs AJ, Abraham D, Denton CP. Endothelial injury in a transforming growth factor β-dependent mouse model of scleroder ma induces pulmonary arterial hypertension. Arthritis Rheum. 2013;65:2928-2939.
52. Iwata K, Ikami K, Matsuno K, et al. Deficiency of NOX1/nicotinamide adenine dinucleotide phosphate, reduced form oxidase leads to pulmonary vascular remodeling. Arterioscler Thromb Vasc Biol. 2014;34:110-119.
53. Norton CE, Broughton BR, Jernigan NL, Walker BR, Resta TC. Enhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase 2. Antioxid Redox Signal. 2013;18:1777-1788.
54. Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C , Heitz F, Page P, Montet X, Michalik L, Arbiser J, Rüegg C, Krause KH, Imhof BA, Imhof B. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism. PLoS One. 2011;6:e14665.
55. Stenmark KR, Davie N, Frid M, Gerasimovskaya E, Das M. Role of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda). 2006;21:134-145.